The information analysis; Yong Ma oversaw the information collection and supervised the information analysis; Xuefeng Shi collected the information, helped create the idea and edited the manuscript. The author(s) read and approved the final manuscript. Funding This study did not obtain any specific grant from funding agencies within the public, commercial, or not-for-profit sectors. Availability of information and components The data that support the findings of this study are available from China Well being Insurance Analysis Association but restrictions apply to the availability of these data, which had been made use of beneath license for the existing study, and so will not be publicly readily available. Information are however out there from the authors uponCompeting interest The authors stated that they had no interests which may be perceived as posing a conflict or bias. Author details 1 School of Management, Beijing University of Chinese Medicine, Beijing, China.FLT3 Protein manufacturer 2 Australian National Institute of Management and Commerce, Eveleigh Sydney, NSW, Australia.XTP3TPA Protein supplier 3 School of Economics and College of Management, Tianjin Normal University, Tianjin, China. four Guangdong Institute for International Strategies, Guangdong University of Foreign Studies, Guangzhou, China. five Newcastle Organization College, University of Newcastle, Newcastle, Callaghan, Australia. 6 Health-related Device Regulatory Investigation and Evaluation Centre, West China Hospital, Sichuan University, Chengdu, China. 7 College of Management, University of Liverpool, Chatham Building, Chatham Street, L697ZH Liverpool, England. eight National Institute of Healthcare Security, Capital Health-related University, Beijing, China. Received: 16 June 2021 Accepted: 11 FebruaryReferences 1. Bolton-Maggs PH, Pasi KJ.PMID:23329650 Haemophilias A and B. Lancet. 2003;361(9371):1801. 2. Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773. three. Cavazza M, Kodra Y, Armeni P, De Santis M, L ez-Bastida J, LinertovR, et al. Social/economic fees and good quality of life in patients with haemophilia in Europe. Eur J Overall health Econ. 2016;17 Suppl 1:535. 4. Qu Y, Nie X, Yang Z, Yin H, Pang Y, Dong P, et al. The prevalence of hemophilia in mainland China: a systematic evaluation and meta-analysis. Southeast Asian J Trop Med Public Well being. 2014;45(2):4556. five. Yang R, Poon MC, Luke KH, Zhao Y, Sun J, Wang X, et al. Constructing a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China. Blood Adv. 2019;3(Suppl 1):34. six. Dou X, Poon MC, Yang R. Haemophilia care in China: Achievements within the previous decade. Haemophilia. 2020;26(five):7597. 7. The ministry of labor and social security on the People’s Republic of China. Simple healthcare insurance coverage, industrial injury insurance drug list (2004 edition). Peking: China labor press; 2004. p. 48. eight. Ministry of human resources and social security of your People’s Republic of China. The ministry of labor and social security with the People’s Republic of China. In: Standard healthcare insurance coverage, industrial injury insurance drug list. 2009 edition. Peking(Beijing), China: China labor press; 2009. p. 52. 9. Ministry of human resources and social safety in the People’s Republic of China. The ministry of human sources and social safety issued a list of medicines for national fundamental healthcare insurance, operate injury insurance coverage and maternity insurance. 2017 edition. 2017. http://gov.cn/xinwen/ 2017-02/23/content_5170392.htm. . Accessed 23 Feb 2017. 10. Sun J, Zhao Y, Yang R, Guan T, Iori.
